特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
613118

世界のヒトインスリン市場:成長、動向、予測

Human Insulin Market - Growth, Trends, and Forecast (2019 - 2024)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 100 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
世界のヒトインスリン市場:成長、動向、予測
出版日: 2019年02月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 100 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のヒトインスリン市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場動向

  • 市場概要
  • 市場促進因子
  • 市場阻害因子
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 製品タイプ別
    • 基礎インスリン、長期作用型インスリン
    • ボーラス投与型または即効型インスリン
    • 従来型ヒトインスリン
    • 併用インスリン
    • 類似インスリン
  • 地域別
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第6章 市場指標

  • 1型糖尿病人口
  • 2型糖尿病人口

第7章 競合環境

  • 企業プロファイル
    • Novo Nordisk AS
    • Sanofi Aventis
    • Eli Lilly
    • Biocon
    • Pfizer
    • Julphar
    • Exir
    • Sedico
    • Wockhardt
  • 企業シェア分析

第8章 市場の機会と将来動向

目次
Product Code: 54429

Market Overview

The global human insulin market is expected to register a CAGR of 4.93% during the forecast period of 2019 - 2024 and is estimated to reach USD 25.7 billion by 2019.

Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world.

Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes.

Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

Scope of the Report

The market is segmented by product type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins) and geography.

Key Market Trends - Growing Obesity and Diabetes Prevalence of Type 2, Especially in Developing Countries

The exact cause of Type 1 diabetes is unknown, but Type 2 diabetes is caused by lifestyle changes happening daily. The prevalence rate of Type 2 diabetes has quadrupled, when compared to 40 years ago. Although oral drugs are considered as a standard care treatment for Type 2 patients, there has been a rise in the need for using insulin, along with the conventional medication, in order to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter into the biosimilar market.

The prevalence of Type 2 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and the primary risk factor for T2DM. Diabetes ranks among the fast-growing chronic diseases in the United States.

India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits. Significant urbanization has enabled physical inactivity and diabetes is a major health concern.

The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients' use, curbing out maximum side effects and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.

North America Dominates the Market

North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region, because of a sedentary lifestyle and launch of new drugs in the region.

The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself.

Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity and rising awareness regarding diabetes care in the region.

Competitive Landscape

The global human insulin market is highly fragmented with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers.

Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine).

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
      • 5.1.1.1 Lantus
      • 5.1.1.2 Levemir
      • 5.1.1.3 Toujeo
      • 5.1.1.4 Tresiba
      • 5.1.1.5 Basaglar
    • 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
      • 5.1.2.1 NovoRapid/Novolog
      • 5.1.2.2 Humalog
      • 5.1.2.3 Apidra
    • 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2024)
      • 5.1.3.1 Novolin/Actrapid/Insulatard
      • 5.1.3.2 Humulin
      • 5.1.3.3 Insuman
    • 5.1.4 Combination Insulins (Value and Volume, 2012-2024)
      • 5.1.4.1 NovoMix
      • 5.1.4.2 Ryzodeg
      • 5.1.4.3 Xultophy
    • 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2024)
      • 5.1.5.1 Insulin Glargine Biosimilars
      • 5.1.5.2 Human Insulin Biosimilars
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2024)
      • 5.2.1.1.1 Basal or Long-acting Insulins
      • 5.2.1.1.2 Bolus or Fast-acting Insulins
      • 5.2.1.1.3 Traditional Human Insulins
      • 5.2.1.1.4 Combination Insulins
      • 5.2.1.1.5 Biosimilar Insulins
      • 5.2.1.2 Canada (Value and Volume, 2012-2024)
      • 5.2.1.2.1 Basal or Long-acting Insulins
      • 5.2.1.2.2 Bolus or Fast-acting Insulins
      • 5.2.1.2.3 Traditional Human Insulins
      • 5.2.1.2.4 Combination Insulins
      • 5.2.1.2.5 Biosimilar Insulins
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
      • 5.2.1.3.1 Basal or Long-acting Insulins
      • 5.2.1.3.2 Bolus or Fast-acting Insulins
      • 5.2.1.3.3 Traditional Human Insulins
      • 5.2.1.3.4 Combination Insulins
      • 5.2.1.3.5 Biosimilar Insulins
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012-2024)
      • 5.2.2.1.1 Basal or Long-acting Insulins
      • 5.2.2.1.2 Bolus or Fast-acting Insulins
      • 5.2.2.1.3 Traditional Human Insulins
      • 5.2.2.1.4 Combination Insulins
      • 5.2.2.1.5 Biosimilar Insulins
      • 5.2.2.2 Germany (Value and Volume, 2012-2024)
      • 5.2.2.2.1 Basal or Long-acting Insulins
      • 5.2.2.2.2 Bolus or Fast-acting Insulins
      • 5.2.2.2.3 Traditional Human Insulins
      • 5.2.2.2.4 Combination Insulins
      • 5.2.2.2.5 Biosimilar Insulins
      • 5.2.2.3 Italy (Value and Volume, 2012-2024)
      • 5.2.2.3.1 Basal or Long-acting Insulins
      • 5.2.2.3.2 Bolus or Fast-acting Insulins
      • 5.2.2.3.3 Traditional Human Insulins
      • 5.2.2.3.4 Combination Insulins
      • 5.2.2.3.5 Biosimilar Insulins
      • 5.2.2.4 Spain (Value and Volume, 2012-2024)
      • 5.2.2.4.1 Basal or Long-acting Insulins
      • 5.2.2.4.2 Bolus or Fast-acting Insulins
      • 5.2.2.4.3 Traditional Human Insulins
      • 5.2.2.4.4 Combination Insulins
      • 5.2.2.4.5 Biosimilar Insulins
      • 5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
      • 5.2.2.5.1 Basal or Long-acting Insulins
      • 5.2.2.5.2 Bolus or Fast-acting Insulins
      • 5.2.2.5.3 Traditional Human Insulins
      • 5.2.2.5.4 Combination Insulins
      • 5.2.2.5.5 Biosimilar Insulins
      • 5.2.2.6 Russia (Value and Volume, 2012-2024)
      • 5.2.2.6.1 Basal or Long-acting Insulins
      • 5.2.2.6.2 Bolus or Fast-acting Insulins
      • 5.2.2.6.3 Traditional Human Insulins
      • 5.2.2.6.4 Combination Insulins
      • 5.2.2.6.5 Biosimilar Insulins
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
      • 5.2.2.7.1 Basal or Long-acting Insulins
      • 5.2.2.7.2 Bolus or Fast-acting Insulins
      • 5.2.2.7.3 Traditional Human Insulins
      • 5.2.2.7.4 Combination Insulins
      • 5.2.2.7.5 Biosimilar Insulins
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012-2024)
      • 5.2.3.1.1 Basal or Long-acting Insulins
      • 5.2.3.1.2 Bolus or Fast-acting Insulins
      • 5.2.3.1.3 Traditional Human Insulins
      • 5.2.3.1.4 Combination Insulins
      • 5.2.3.1.5 Biosimilar Insulins
      • 5.2.3.2 Brazil (Value and Volume, 2012-2024)
      • 5.2.3.2.1 Basal or Long-acting Insulins
      • 5.2.3.2.2 Bolus or Fast-acting Insulins
      • 5.2.3.2.3 Traditional Human Insulins
      • 5.2.3.2.4 Combination Insulins
      • 5.2.3.2.5 Biosimilar Insulins
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
      • 5.2.3.3.1 Basal or Long-acting Insulins
      • 5.2.3.3.2 Bolus or Fast-acting Insulins
      • 5.2.3.3.3 Traditional Human Insulins
      • 5.2.3.3.4 Combination Insulins
      • 5.2.3.3.5 Biosimilar Insulins
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012-2024)
      • 5.2.4.1.1 Basal or Long-acting Insulins
      • 5.2.4.1.2 Bolus or Fast-acting Insulins
      • 5.2.4.1.3 Traditional Human Insulins
      • 5.2.4.1.4 Combination Insulins
      • 5.2.4.1.5 Biosimilar Insulins
      • 5.2.4.2 South Korea (Value and Volume, 2012-2024)
      • 5.2.4.2.1 Basal or Long-acting Insulins
      • 5.2.4.2.2 Bolus or Fast-acting Insulins
      • 5.2.4.2.3 Traditional Human Insulins
      • 5.2.4.2.4 Combination Insulins
      • 5.2.4.2.5 Biosimilar Insulins
      • 5.2.4.3 China (Value and Volume, 2012-2024)
      • 5.2.4.3.1 Basal or Long-acting Insulins
      • 5.2.4.3.2 Bolus or Fast-acting Insulins
      • 5.2.4.3.3 Traditional Human Insulins
      • 5.2.4.3.4 Combination Insulins
      • 5.2.4.3.5 Biosimilar Insulins
      • 5.2.4.4 India (Value and Volume, 2012-2024)
      • 5.2.4.4.1 Basal or Long-acting Insulins
      • 5.2.4.4.2 Bolus or Fast-acting Insulins
      • 5.2.4.4.3 Traditional Human Insulins
      • 5.2.4.4.4 Combination Insulins
      • 5.2.4.4.5 Biosimilar Insulins
      • 5.2.4.5 Australia (Value and Volume, 2012-2024)
      • 5.2.4.5.1 Basal or Long-acting Insulins
      • 5.2.4.5.2 Bolus or Fast-acting Insulins
      • 5.2.4.5.3 Traditional Human Insulins
      • 5.2.4.5.4 Combination Insulins
      • 5.2.4.5.5 Biosimilar Insulins
      • 5.2.4.6 Vietnam (Value and Volume, 2012-2024)
      • 5.2.4.6.1 Basal or Long-acting Insulins
      • 5.2.4.6.2 Bolus or Fast-acting Insulins
      • 5.2.4.6.3 Traditional Human Insulins
      • 5.2.4.6.4 Combination Insulins
      • 5.2.4.6.5 Biosimilar Insulins
      • 5.2.4.7 Malaysia (Value and Volume, 2012-2024)
      • 5.2.4.7.1 Basal or Long-acting Insulins
      • 5.2.4.7.2 Bolus or Fast-acting Insulins
      • 5.2.4.7.3 Traditional Human Insulins
      • 5.2.4.7.4 Combination Insulins
      • 5.2.4.7.5 Biosimilar Insulins
      • 5.2.4.8 Indonesia (Value and Volume, 2012-2024)
      • 5.2.4.8.1 Basal or Long-acting Insulins
      • 5.2.4.8.2 Bolus or Fast-acting Insulins
      • 5.2.4.8.3 Traditional Human Insulins
      • 5.2.4.8.4 Combination Insulins
      • 5.2.4.8.5 Biosimilar Insulins
      • 5.2.4.9 Philippines (Value and Volume, 2012-2024)
      • 5.2.4.9.1 Basal or Long-acting Insulins
      • 5.2.4.9.2 Bolus or Fast-acting Insulins
      • 5.2.4.9.3 Traditional Human Insulins
      • 5.2.4.9.4 Combination Insulins
      • 5.2.4.9.5 Biosimilar Insulins
      • 5.2.4.10 Thailand (Value and Volume, 2012-2024)
      • 5.2.4.10.1 Basal or Long-acting Insulins
      • 5.2.4.10.2 Bolus or Fast-acting Insulins
      • 5.2.4.10.3 Traditional Human Insulins
      • 5.2.4.10.4 Combination Insulins
      • 5.2.4.10.5 Biosimilar Insulins
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
      • 5.2.4.11.1 Basal or Long-acting Insulins
      • 5.2.4.11.2 Bolus or Fast-acting Insulins
      • 5.2.4.11.3 Traditional Human Insulins
      • 5.2.4.11.4 Combination Insulins
      • 5.2.4.11.5 Biosimilar Insulins
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
      • 5.2.5.1.1 Basal or Long-acting Insulins
      • 5.2.5.1.2 Bolus or Fast-acting Insulins
      • 5.2.5.1.3 Traditional Human Insulins
      • 5.2.5.1.4 Combination Insulins
      • 5.2.5.1.5 Biosimilar Insulins
      • 5.2.5.2 Iran (Value and Volume, 2012-2024)
      • 5.2.5.2.1 Basal or Long-acting Insulins
      • 5.2.5.2.2 Bolus or Fast-acting Insulins
      • 5.2.5.2.3 Traditional Human Insulins
      • 5.2.5.2.4 Combination Insulins
      • 5.2.5.2.5 Biosimilar Insulins
      • 5.2.5.3 Egypt (Value and Volume, 2012-2024)
      • 5.2.5.3.1 Basal or Long-acting Insulins
      • 5.2.5.3.2 Bolus or Fast-acting Insulins
      • 5.2.5.3.3 Traditional Human Insulins
      • 5.2.5.3.4 Combination Insulins
      • 5.2.5.3.5 Biosimilar Insulins
      • 5.2.5.4 Oman (Value and Volume, 2012-2024)
      • 5.2.5.4.1 Basal or Long-acting Insulins
      • 5.2.5.4.2 Bolus or Fast-acting Insulins
      • 5.2.5.4.3 Traditional Human Insulins
      • 5.2.5.4.4 Combination Insulins
      • 5.2.5.4.5 Biosimilar Insulins
      • 5.2.5.5 South Africa (Value and Volume, 2012-2024)
      • 5.2.5.5.1 Basal or Long-acting Insulins
      • 5.2.5.5.2 Bolus or Fast-acting Insulins
      • 5.2.5.5.3 Traditional Human Insulins
      • 5.2.5.5.4 Combination Insulins
      • 5.2.5.5.5 Biosimilar Insulins
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
      • 5.2.5.6.1 Basal or Long-acting Insulins
      • 5.2.5.6.2 Bolus or Fast-acting Insulins
      • 5.2.5.6.3 Traditional Human Insulins
      • 5.2.5.6.4 Combination Insulins
      • 5.2.5.6.5 Biosimilar Insulins

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2024)
  • 6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk AS
    • 7.1.2 Sanofi Aventis
    • 7.1.3 Eli Lilly
    • 7.1.4 Biocon
    • 7.1.5 Pfizer
    • 7.1.6 Julphar
    • 7.1.7 Exir
    • 7.1.8 Sedico
    • 7.1.9 Wockhardt
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.